Related Experiment Video
Updated: Jun 21, 2026
07:51
Effect of Anti-c-fms Antibody on Osteoclast Formation and Proliferation of Osteoclast Precursor In Vitro
Published on: March 18, 2019
Macrophage migration inhibitory factor inhibits osteoclastogenesis
Claire Jacquin1, Boguslawa Koczon-Jaremko, Hector L Aguila
1Center for Immunotherapy, University of Connecticut Health Center, Farmington, CT, USA.
Bone
|July 14, 2009
Summary
Macrophage migration inhibitory factor (MIF) inhibits osteoclast formation in vitro. MIF deficiency in mice leads to increased osteoclastogenesis and reduced bone mass, suggesting MIF regulates bone turnover.
Area of Science:
- Immunology
- Bone Biology
- Cell Biology
Background:
- Macrophage migration inhibitory factor (MIF) is a key regulator of innate and adaptive immunity.
- MIF is produced by various immune cells, including T cells and macrophages.
- Osteoclastogenesis, the formation of bone-resorbing cells, is crucial for bone remodeling.
Purpose of the Study:
- To investigate the role of MIF in osteoclastogenesis.
- To determine the effect of MIF on bone mass in vivo.
- To elucidate the mechanisms by which MIF influences bone metabolism.
Main Methods:
- Bone marrow cultures from wild-type (WT) and MIF-deficient (KO) mice were used to assess osteoclast formation.
- Osteoclast differentiation was induced using M-CSF and RANKL, PTH, or vitamin D.
- Bone mass and serum markers of bone turnover were analyzed in WT and MIF KO mice.
Main Results:
- Exogenous MIF inhibited osteoclast formation in vitro by reducing cell fusion.
- MIF-deficient bone marrow cultures showed significantly increased osteoclast numbers compared to WT controls.
- MIF KO mice exhibited decreased trabecular bone volume and reduced serum bone turnover markers.
Conclusions:
- MIF acts as an inhibitor of osteoclastogenesis in vitro.
- MIF deficiency leads to enhanced osteoclast formation and decreased bone mass.
- MIF may indirectly regulate bone turnover in vivo.
